Health X targets ₹6,000 cr FY30 revenue, Q1 hits ₹400 cr
FY26 revenue rose 18% to ₹1,283 cr, EBITDA loss narrowed to ₹65 cr. Management targets 5x growth with ₹424 cr warehouse capex, partly debt-funded.
— 3 earlier stories on Health X Platform Ltd. →What's new
- FY26 revenue ₹1,283 cr (+18% YoY); EBITDA loss narrowed to ₹65 cr from ₹79 cr.
- Long-term target of ₹6,000 cr by FY30, split ₹4,000 cr B2B and ₹2,000 cr B2C.
- ₹424 cr warehousing capex announced, partially funded by ₹154 cr bank loans.
- Q1FY27 revenue tracking at ₹400 cr, a historic best quarterly print.
Why this matters
The FY30 target implies roughly 5x growth from FY26 levels. Management is betting on warehousing and B2B retail while adding debt to a debt-free balance sheet. The company remains loss-making, and the record Q1 run rate still falls short of the ambition.
What we're watching
- Execution of ₹424 cr warehouse capex and its impact on margins.
- JITHO generics scaling beyond current ₹30 lakh/month.
- Q1FY27 actual results when reported, versus the ₹400 cr tracking.
The full read
Health X Platform delivered an 18% revenue increase to ₹1,283 cr in FY26 and narrowed its EBITDA loss to ₹65 cr from ₹79 cr. That's the backward look. The forward look is far more ambitious: management targets ₹6,000 cr in revenue by FY30. To get there, it plans ₹424 cr in warehouse capex, partly funded by ₹154 cr in bank loans, its first debt. Q1FY27 revenue tracking at ₹400 cr is a record quarterly print. JITHO private-label generics are early at ₹30 lakh per month. AI tools are built but on hold. The ambition is clear. The numbers need to catch up.
Questions answered
- How credible is the ₹6,000 cr FY30 target?
- It requires roughly 5x revenue growth from FY26. Current Q1 run rate is ₹400 cr, but management has not provided a detailed path to the target. Execution risk is high.
- How is the ₹424 cr warehousing capex funded?
- ₹154 cr comes from bank loans, the rest from internal accruals or other sources. This is the first debt on the company's balance sheet (debt/equity was 0.00).
- What is JITHO and its current traction?
- JITHO is Health X's private-label generic medicines brand. Early sales are ₹30 lakh per month, which is negligible relative to the company's overall revenue.
- Why haven't AI tools been rolled out?
- Management said the tools are built but await 'market readiness' before launch. No timeline was provided.
- What is the status of the Microsec Resources demerger?
- The demerger is progressing as previously disclosed. No new details were given in this call.
Health X Platform Ltd.
Latest quarter · Mar 2026
Leverage & growth
Story so far
All notes on HEALTHX →- 12 Jun 2026 · 5:15 PM IST Health X targets ₹6,000 cr FY30 revenue, Q1 hits ₹400 cr
- 7d ago Health X splits its tiny finance arm, absorbs core healthcare unit into parent
- 12d ago Health X promoter sheds 0.79% stake for ₹7.5 cr
- 26d ago Health X Platform sets date for FY26 results